1. Is mRNA technology an existential threat to animal and human life? Read the Open Letter of Concern and you decide ...
2. Understanding the dangers and likelihood of a false positive result from PCR testing and why they shouldn't be relied upon
3. Questioning the necessity for Bovaer, and why methane isn't an issue when Net Zero is based on the greenhouse gas myth
4. mRNA technology is still an existential threat to animal and human life. Read the new follow up Open Letter of Concern 2

logo_animation_corrected.gifQuantum Veterinary Medicine at your Service

Open Letter of Concern 2

Open Letter of Concern 2

27 Aug 2025 admin

To:

1.      Dr Christine Middlemiss BVMS, M.R.C.V.S., Chief Veterinary Officer at DEFRA & VMD

2.      Abigail Seager, Director and CEO, VMD

3.      Gavin Hall, Deputy CEO and Director of Authorisations, VMD

4.      David Catlow, M.R.C.V.S., non-executive Director VMD

5.      Alison White, non-executive Director VMD

6.      Laura Catterick, non-executive Director VMD

Further to my original Open Letter of Concern from July 2023, I am alarmed and further concerned to hear that the Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) has signed a memorandum of understanding with CPI to focus on the development of RNA vaccine platforms for use in livestock.

The original Open Letter of Concern, co-signed by myself, Dr Kevin McCairn Ph.D, R. M. Thornsberry D.V.M., M.B.A., Chairman Animal Health Committee, R-CALF-USA, and Dr Siguna Mueller, Ph.D, Ph.D highlighted and evidenced the known and scientifically proven dangers associated with the use of the mRNA platform from the lipid nanoparticles, the mRNA itself, and potential dangers from whatever protein would be constructed, both intentionally and potentially unintentionally. These dangers extend to the saRNA and taRNA platforms and any other variations/developments of the mRNA technology.
 
These dangers include but are not limited to inflammation, clumping to form emboli, alteration of recipient genome, introduction of plasmid and/or other biological material, interference with microRNA cell signalling, prionogenic and/or amyloidogenic activity, and immune dysfunction including autoimmunity and all sequelae arising from these.
 
These are all highly dangerous known side-effects; with perhaps the most important of these being the prionogenic activity because of the danger from prions to not only the recipient, but to humans if used within the food chain as we have experienced before from BSE. I would also add the consequences of shedding to the above dangers list – whether the mRNA and/or whatever protein is produced under direction. If the shed material were to be prionogenic this could lead to significant environmental contamination with potentially devastating consequences.
 
From statements made by Professor Bryan Charleston MRCVS FRS, Director of The Pirbright Institute, the declared collaboration between CVIM and CPI clearly intends the development and manufacture of RNA products given that CPI’s RNA Centre of Excellence facility in Darlington is reportedly the only site in the UK capable of developing and manufacturing “lipid nanoparticle encapsulated” messenger and self-amplifying RNA vaccines. The dangers listed above cannot be avoided.
 
There has been further research beyond that provided in the original Open Letter of Concern which does not allay the fears expressed 2 years ago. On the contrary, there is further evidence to support these original concerns. The more recent understanding is that prions remain infectious in the environment for considerably longer than was previously thought and can be taken up by plants through their roots and redistributed to the edible parts of plants. This aetiology has been determined to be part of how Chronic Wasting Disease in deer has been spread in the USA.
 
I used AI to summarise my blog and 19 prion research papers to summarise the risks from use in livestock. You can view the resultant video and audio summaries here.

The evidence emerging from the USA as shown in the 2 graphs below, is beyond concerning in that there would appear to be epigenetic risks from females being administered the mRNA platform during pregnancy. The increase in deaths in the 0-4 year old age range amongst individuals who were not vaccinated and did not contract COVID, but whose mothers were vaccinated during pregnancy has huge implications for using the mRNA platform in the livestock industry that relies totally on successful breeding to maintain numbers and thus our food supply.

and

The intended collaboration and research would not be happening unless these products are intended to be authorised and widely used commercially. Given that trials to prove safety would have to undertaken over a considerable length of time and would still not necessarily guarantee that prions could not be generated, it would be commercially prudent to stop now. I do not see how DEFRA could authorise trials, or how the VMD could possibly authorise any mRNA products given their lack of safety and efficacy to date. This is why the US Government has stopped the vast majority of mRNA research funding. Dr Robert Malone who was one of the early developers of this technology has spoken out about the dangers of the mRNA platform. Taking up the slack in the market when US research has been stopped over concerns for safety smacks of putting commercialism before health and safety, not only for the animals but human health and safety too.

The MHRA, ONS and other Government bodies may not be processing or publicising the equivalent figures for the UK, but that doesn’t make the mRNA platform safe.

Conclusion

Once again, we would like to know as a Freedom of Information request whether there are any ongoing or intended mRNA/saRNA/taRNA or similar trials for the UK in any animal species, or any authorisation processes underway or planned that DEFRA/VMD are aware of.

Furthermore, we, the undersigned would be grateful for your assurance that no authorisation will be permitted in future without evidence to guarantee that none of adverse events described in both Letters of Concern to date can possibly occur.

Signed…

Roger S. Meacock BVSc., M.R.C.V.S.

Dr Kevin McCairn Ph.D

R. M. Thornsberry D.V.M., M.B.A., Chairman Animal Health Committee, R-CALF-USA

Dr Siguna Mueller, Ph.D, Ph.D

Anja Søndergaard DVM  

Judy Jasek, DVM

Laura Allison, DVM

Dr Tess Lawrie, MBBCh, PhD. World Council for Health

Christof Plothe DO, World Council for Health

Dr. Markos Christidis, MD

Alan J. Slater BVMS, MRCVS, MSc, MSc, DC, DAC, MMCA, GCC, DVetHom, DHM, OSDipCTh, DipLC, BSc[Hons][Psych], BA[Hons][Music], DMus, DCK, DCBT,  DA(LN), DAP. CCS, FBIH

Prof. Polyxeni Nicolopoulou Stamati MD.PhD.

Mark Trozzi MD

 
References

Originally provided for the first Open Letter of Concern plus new references below.

  1. Le, T., Sun, C., Chang, J., Zhang, G. & Yin, X. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases. Viruses 14 (2022). https://doi.org:10.3390/v14020401
  2. News, G. E. B. Bayer Partners with BioNTech to Develop mRNA Vaccines, Drugs for Animal Health, <https://www.genengnews.com/topics/drug-discovery/bayer-partners-with-biontech-to-develop-mrna-vaccines-drugs-for-animal-health/> (2023).
  3. Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468 (1990). https://doi.org:10.1126/science.1690918
  4. Ndeupen, S. et al. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021). https://doi.org:10.1016/j.isci.2021.103479
  5. Kulkarni, J. A. et al. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano 12, 4787-4795 (2018). https://doi.org:10.1021/acsnano.8b01516
  6. Faizullin, D., Valiullina, Y., Salnikov, V. & Zuev, Y. Direct interaction of fibrinogen with lipid microparticles modulates clotting kinetics and clot structure. Nanomedicine 23, 102098 (2020). https://doi.org:10.1016/j.nano.2019.102098
  7. Gindy, M. E. et al. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics. Mol Pharm 11, 4143-4153 (2014). https://doi.org:10.1021/mp500367k
  8. Merian, J. et al. Comparative biodistribution in mice of cyanine dyes loaded in lipid nanoparticles. Eur J Pharm Biopharm 93, 1-10 (2015). https://doi.org:10.1016/j.ejpb.2015.03.019
  9. Merian, J. et al. Synthetic lipid nanoparticles targeting steroid organs. J Nucl Med 54, 1996-2003 (2013). https://doi.org:10.2967/jnumed.113.121657
  10. Domazet-Loso, T. mRNA Vaccines: Why Is the Biology of Retroposition Ignored? Genes (Basel) 13 (2022). https://doi.org:10.3390/genes13050719
  11. Doerfler, W. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines? Virus Res 302, 198466 (2021). https://doi.org:10.1016/j.virusres.2021.198466
  12. Sattar, S. et al. Nuclear translocation of spike mRNA and protein is a novel feature of SARS-CoV-2. Front Microbiol 14, 1073789 (2023). https://doi.org:10.3389/fmicb.2023.1073789
  13. Yeo, J. H. & Chong, M. M. Many routes to a micro RNA. IUBMB Life 63, 972-978 (2011). https://doi.org:10.1002/iub.524
  14. Kozomara, A., Birgaoanu, M. & Griffiths-Jones, S. miRBase: from microRNA sequences to function. Nucleic Acids Research 47, D155-D162 (2018). https://doi.org:10.1093/nar/gky1141
  15. Miyashita, Y. et al. Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination. npj Vaccines 7, 16 (2022). https://doi.org:10.1038/s41541-022-00439-3
  16. Wells, G. A. et al. A novel progressive spongiform encephalopathy in cattle. Vet Rec 121, 419-420 (1987). https://doi.org:10.1136/vr.121.18.419
  17. Bruce, M. E. et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389, 498-501 (1997). https://doi.org:10.1038/39057
  18. Goedert, M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 349, 1255555 (2015). https://doi.org:10.1126/science.1255555
  19. Tetz, G. & Tetz, V. Prion-like Domains in Eukaryotic Viruses. Scientific Reports 8, 8931 (2018). https://doi.org:10.1038/s41598-018-27256-w
  20. Woerman, A. L. & Tamgüney, G. Body-first Parkinson’s disease and variant Creutzfeldt–Jakob disease – similar or different? Neurobiology of Disease 164, 105625 (2022). https://doi.org:https://doi.org/10.1016/j.nbd.2022.105625
  21. Nystrom, S. & Hammarstrom, P. Amyloidogenesis of SARS-CoV-2 Spike Protein. J Am Chem Soc 144, 8945-8950 (2022). https://doi.org:10.1021/jacs.2c03925
  22. Laudicella, R. et al. Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination. SN Comprehensive Clinical Medicine 3, 2626-2628 (2021). https://doi.org:10.1007/s42399-021-01058-0
  23. Leung, W.-Y., Wu, H. H. L., Floyd, L., Ponnusamy, A. & Chinnadurai, R. COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently? Vaccines 11, 1139 (2023).
  24. Kovachev, P. S. et al. RNA modulates aggregation of the recombinant mammalian prion protein by direct interaction. Sci Rep 9, 12406 (2019). https://doi.org:10.1038/s41598-019-48883-x
  25. Perez, J.-C., Moret-Chalmin, C. & Montagnier, L. Emergence of a New Creutzfeldt-Jakob Disease: 26 Cases of the Human Version of Mad-Cow Disease, Days After a COVID-19 Injection. International Journal of Vaccine Theory, Practice, and Research 3, 727-770 (2023). https://doi.org:10.56098/ijvtpr.v3i1.66
  26. Hosseini, R. & Askari, N. A review of neurological side effects of COVID-19 vaccination. European Journal of Medical Research 28, 102 (2023). https://doi.org:10.1186/s40001-023-00992-0
  27. Irrgang, P. et al. (2023). Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol 8, eade2798. https://doi.org:10.1126/sciimmunol.ade2798

Additional references for this Open Letter of Concern 2.

  1. Kong, Y., Huang, P., Shi, Q., Wang, Y., Li, M., Ma, J., … Zou, W. Q. (2025). Prion 2024 conference: from two decades of growth to a new journey forward. Prion, 19(1), 1–7. https://doi.org/10.1080/19336896.2025.2514569
  2. Grunklee, M. K., Lichtenberg, S. S., Lurndahl, N. A., Schwabenlander, M. D., Karwan, D. L., Li, E. A., … Wolf, T. M. (2025). Detection of chronic wasting disease prions in soil at an illegal white-tailed deer carcass disposal site. Prion, 19(1), 8–19. https://doi.org/10.1080/19336896.2025.2514947
  3. Davenport K.A., Henderson D.M., Bian J., Telling G.C., Mathiason C.K., Hoover E.A.. (2015). Insights into chronic wasting disease and bovine spongiform encephalopathy species barriers by use of real-time conversion. J Virol. 89:9524 –9531. doi:10.1128/JVI.01439-15.
  4. Carlson C.M., Thomas S., Keating M.W., Soto P., Gibbs N.M., Chang H., Wiepz J.K., Austin A.G., Schneider J.R., Morales R., Johnson C.J., Pedersen J.A,. (2023). Plants as vectors for environmental prion transmission. iScience, Volume 26, Issue 12, 108428, ISSN 2589-0042, https://doi.org/10.1016/j.isci.2023.108428.
  5. Kokemuller R.D., Moore S.J., Bian J., West Greenlee M.H., Greenlee J.J.. (2023) Disease phenotype of classical sheep scrapie is changed upon experimental passage through white-tailed deer. PLoS Pathog 19(12): e1011815. https://doi.org/10.1371/journal.ppat.1011815
  6. Pritzkow S., Morales R., Lyon A., Concha-Marambio L., Urayama A., Soto C.. Efficient prion disease transmission through common environmental materials. J Biol Chem. 2018 Mar 2;293(9):3363-3373. doi: 10.1074/jbc.M117.810747. Epub 2018 Jan 12. PMID: 29330304; PMCID: PMC5836136.
  7. Pritzkow S., Gorski D., Ramirez F., Soto C.. (2021). Prion dissemination through the environment and medical practices: facts and risks for human health. Clin Microbiol Rev 34:e00059-19. https://doi.org/10.1128/CMR.00059-19.
  8. Hannaoui S., Zemlyankina I., Chang S.C., Arifin M.I., Béringue V., McKenzie D., Schatzl H.M., Gilch S.. Transmission of cervid prions to humanized mice demonstrates the zoonotic potential of CWD. Acta Neuropathol. 2022 Oct;144(4):767-784. doi: 10.1007/s00401-022-02482-9. Epub 2022 Aug 22. PMID: 35996016; PMCID: PMC9468132.
  9. Kell DB, Pretorius E. Proteomic Evidence for Amyloidogenic Cross-Seeding in Fibrinaloid Microclots. Int J Mol Sci. 2024 Oct 8;25(19):10809. doi: 10.3390/ijms251910809. PMID: 39409138; PMCID: PMC11476703.
  10. https://theethicalskeptic.com/2025/08/19/houston-we-have-another-problem/

Share this page:

Last Post

Bovaer Open Letter

Next Post

Vegan Pet Food Insanity

Topics
Related Posts
Open Letter of Concern 2
Vegan Pet Food Insanity 2
The Life of Prion

Call for Signatures

If any veterinarian, doctor or relevant scientist would like to add their signature to this Open Letter of Concern 2, please email me.

Signatures are added in order of agreeing to sign.